ANI Pharmaceuticals (NASDAQ:ANIP) Cut to “Hold” at BidaskClub
Other analysts have also issued research reports about the stock. Zacks Investment Research lowered shares of ANI Pharmaceuticals from a buy rating to a hold rating in a research note on Friday, May 17th. Raymond James lowered shares of ANI Pharmaceuticals from a strong-buy rating to an outperform rating and upped their target price for the stock from $73.00 to $82.00 in a research note on Friday, May 10th. ValuEngine upgraded shares of ANI Pharmaceuticals from a hold rating to a buy rating in a research note on Thursday, May 9th. Canaccord Genuity reiterated a buy rating and issued a $90.00 target price (up previously from $80.00) on shares of ANI Pharmaceuticals in a research note on Monday, May 13th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $89.00 target price on shares of ANI Pharmaceuticals in a research note on Thursday, May 9th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. ANI Pharmaceuticals has an average rating of Buy and a consensus target price of $84.50.
ANIP stock opened at $69.68 on Tuesday. The stock has a market capitalization of $851.78 million, a price-to-earnings ratio of 15.11 and a beta of 2.23. The company has a debt-to-equity ratio of 0.33, a quick ratio of 0.67 and a current ratio of 0.92. ANI Pharmaceuticals has a 12 month low of $36.92 and a 12 month high of $74.00.
In other news, Director David Nash bought 1,445 shares of ANI Pharmaceuticals stock in a transaction dated Friday, May 24th. The stock was purchased at an average price of $68.76 per share, for a total transaction of $99,358.20. Following the purchase, the director now directly owns 5,236 shares in the company, valued at approximately $360,027.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Arthur Przybyl sold 27,625 shares of the company’s stock in a transaction on Tuesday, March 19th. The stock was sold at an average price of $63.53, for a total transaction of $1,755,016.25. The disclosure for this sale can be found here. In the last quarter, insiders sold 78,536 shares of company stock valued at $5,340,131. Company insiders own 24.70% of the company’s stock.
Several large investors have recently modified their holdings of the stock. Financial Gravity Wealth Inc. bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $54,000. Quantamental Technologies LLC increased its stake in ANI Pharmaceuticals by 169.4% in the first quarter. Quantamental Technologies LLC now owns 862 shares of the specialty pharmaceutical company’s stock valued at $61,000 after purchasing an additional 542 shares in the last quarter. South Dakota Investment Council bought a new stake in ANI Pharmaceuticals in the fourth quarter valued at approximately $45,000. BNP Paribas Arbitrage SA increased its stake in ANI Pharmaceuticals by 55,466.7% in the first quarter. BNP Paribas Arbitrage SA now owns 1,667 shares of the specialty pharmaceutical company’s stock valued at $118,000 after purchasing an additional 1,664 shares in the last quarter. Finally, Truvestments Capital LLC bought a new stake in ANI Pharmaceuticals in the first quarter valued at approximately $140,000. 63.92% of the stock is currently owned by institutional investors.
About ANI Pharmaceuticals
ANI Pharmaceuticals, Inc, a specialty pharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncolytics (anti-cancers), hormones and steroids, and other formulations. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract manufacturing for other pharmaceutical companies.
Further Reading: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.